Sabine Hermans MD, MSc, PhD is a post-doctoral fellow at the Amsterdam Institute for Global Health and Development and Department of Global Health, University of Amsterdam. She is currently based at the Desmond Tutu HIV Centre at the University of Cape Town, South Africa.
Sabine trained as an internist and infectious diseases specialist in the Netherlands. From 2008 to 2012 she was based at the Infectious Diseases Institute (IDI), part of Makerere University College of Health Sciences in Kampala, Uganda, seconded by the University of Utrecht and later the Amsterdam Institute for Global Health and Development. She set up and headed the integrated TB/HIV clinic at the IDI, which she combined with research leading toward the completion of her PhD at the University of Utrecht in June 2012. She subsequently moved to the London School of Hygiene and Tropical Medicine, where she obtained her MSc in Epidemiology in 2013.
A 3 year post-doctoral fellowship granted by the European Commission allowed Sabine to join the Desmond Tutu HIV Centre at the University of Cape Town, seconded by AIGHD, in October 2013. She is currently working on epidemiological analyses of a decade of data on tuberculosis in the City of Cape Town, with the aim of developing a mathematical model of TB in the city. She also works as a clinician at the Hannan Crusaid Antiretroviral Treatment Centre in Gugulethu, Cape Town.
Her research interests include epidemiology of HIV and TB co-infection and operational research into the implementation of optimal strategies of health care delivery. She has also undertaken historical and cost-effectiveness research in this field. She was the principal investigator of a prospective non-randomised interventional study of the effect of a Short Message Service (SMS) reminder service on improving TB treatment completion in Uganda. In 2011 she was awarded the annual International AIDS Society TB-HIV research prize for her operational research on antiretroviral treatment initiation at the IDI integrated TB-HIV clinic.
The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study
Tuberculosis in Cape Town: An age structured transmission model
Tuberculosis in Cape Town: An age‑structured transmission model
Authored by: Blaser Nello, Zahnd Cindy, Hermans Sabine, Salazar‑Vizcaya Luisa, Estill Janne, Morrow Carl, Egger Matthias, Keiser Olivia, Wood Robin
In: EPIDEMICS 14, 2016, p.54‑61.
A Century of Tuberculosis Epidemiology in the Northern and Southern Hemisphere: The Differential Impact of Control Interventions
Authored by: Hermans S. M., Horsburgh CR, Wood R.
In: PloS One, 2015
Impact of Anti-Retroviral Treatment and Cotrimoxazole Prophylaxis on Helminth Infections in HIV-Infected Patients in Lambaréné, Gabon.
Antiretroviral therapy and tuberculosis: does the regimen matter?
Authored by: van Leth F., Wit Ferdinand W. M. N., Hermans S. M.
In: Expert Reviews of Anti-Infective Therapy, 2014
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda
Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery
Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study
Comment on: Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia
Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study
Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda
Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis
Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda